BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 36266450)

  • 41. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways.
    Ghayad SE; Vendrell JA; Ben Larbi S; Dumontet C; Bieche I; Cohen PA
    Int J Cancer; 2010 Jan; 126(2):545-62. PubMed ID: 19609946
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Multi-time scale transcriptomic analysis on the dynamic process of tamoxifen resistance development in breast cancer cell lines.
    Zeng Q; Lin X; Chen H; Yan Y; Wang X
    Breast Cancer; 2022 May; 29(3):458-467. PubMed ID: 35041152
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Reversal of endocrine resistance in breast cancer: interrelationships among 14-3-3ζ, FOXM1, and a gene signature associated with mitosis.
    Bergamaschi A; Christensen BL; Katzenellenbogen BS
    Breast Cancer Res; 2011 Jun; 13(3):R70. PubMed ID: 21707964
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The forkhead transcription factor FOXM1 promotes endocrine resistance and invasiveness in estrogen receptor-positive breast cancer by expansion of stem-like cancer cells.
    Bergamaschi A; Madak-Erdogan Z; Kim YJ; Choi YL; Lu H; Katzenellenbogen BS
    Breast Cancer Res; 2014 Sep; 16(5):436. PubMed ID: 25213081
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Loss of B-cell translocation gene 2 expression in estrogen receptor-positive breast cancer predicts tamoxifen resistance.
    Takahashi M; Hayashida T; Okazaki H; Miyao K; Jinno H; Kitagawa Y
    Cancer Sci; 2014 Jun; 105(6):675-82. PubMed ID: 24698107
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hormonal Therapy Resistance and Breast Cancer: Involvement of Adipocytes and Leptin.
    Delort L; Bougaret L; Cholet J; Vermerie M; Billard H; Decombat C; Bourgne C; Berger M; Dumontet C; Caldefie-Chezet F
    Nutrients; 2019 Nov; 11(12):. PubMed ID: 31756890
    [TBL] [Abstract][Full Text] [Related]  

  • 47. MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer.
    Ward A; Shukla K; Balwierz A; Soons Z; König R; Sahin O; Wiemann S
    J Pathol; 2014 Aug; 233(4):368-79. PubMed ID: 24752803
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Sensitivity to further endocrine therapy is retained following progression on first-line fulvestrant.
    Robertson JF; Howell A; Gorbunova VA; Watanabe T; Pienkowski T; Lichinitser MR
    Breast Cancer Res Treat; 2005 Jul; 92(2):169-74. PubMed ID: 15986127
    [TBL] [Abstract][Full Text] [Related]  

  • 49. SOX4-mediated FBW7 transcriptional upregulation confers Tamoxifen resistance in ER+ breast cancers via GATA3 downregulation.
    Sharma A; Thacker G; Mishra M; Singh AK; Upadhyay V; Sanyal S; Trivedi AK
    Life Sci; 2022 Aug; 303():120682. PubMed ID: 35662647
    [TBL] [Abstract][Full Text] [Related]  

  • 50. miR-484 suppresses endocrine therapy-resistant cells by inhibiting KLF4-induced cancer stem cells in estrogen receptor-positive cancers.
    Wei Y; Li H; Qu Q
    Breast Cancer; 2021 Jan; 28(1):175-186. PubMed ID: 32865695
    [TBL] [Abstract][Full Text] [Related]  

  • 51. HMGB1 is a key factor for tamoxifen resistance and has the potential to predict the efficacy of CDK4/6 inhibitors in breast cancer.
    Zhang H; Wang J; Li J; Zhou X; Yin L; Wang Y; Gu Y; Niu X; Yang Y; Ji H; Zhang Q
    Cancer Sci; 2021 Apr; 112(4):1603-1613. PubMed ID: 33453094
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Stemness Phenotype in Tamoxifen Resistant Breast Cancer Cells May be Induced by Interactions Between Receptor Tyrosine Kinases and ERα-66.
    Farahmand L; Mansouri S; Jafarbeik-Iravani N; Teymourzadeh A; Majidzadeh-A K
    Recent Pat Anticancer Drug Discov; 2018; 13(3):302-307. PubMed ID: 29512469
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Oestrogen Non-Genomic Signalling is Activated in Tamoxifen-Resistant Breast Cancer.
    Poulard C; Jacquemetton J; Trédan O; Cohen PA; Vendrell J; Ghayad SE; Treilleux I; Marangoni E; Le Romancer M
    Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31195751
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tamoxifen stimulates the growth of cyclin D1-overexpressing breast cancer cells by promoting the activation of signal transducer and activator of transcription 3.
    Ishii Y; Waxman S; Germain D
    Cancer Res; 2008 Feb; 68(3):852-60. PubMed ID: 18245487
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Deregulation of IGF-binding proteins -2 and -5 contributes to the development of endocrine resistant breast cancer in vitro.
    Hawsawi Y; Humphries MP; Wright A; Berwick A; Shires M; Al-Kharobi H; El-Gendy R; Jove M; Twelves C; Speirs V; Beattie J
    Oncotarget; 2016 May; 7(22):32129-43. PubMed ID: 27050076
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A771726, an anti-inflammatory drug, exerts an anticancer effect and reverses tamoxifen resistance in endocrine-resistant breast cancer cells.
    Huang O; Xie Z; Zhang W; Lou Y; Mao Y; Liu H; Jiang M; Shen K
    Oncol Rep; 2014 Aug; 32(2):627-34. PubMed ID: 24919713
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The ER-alpha mutation Y537S confers Tamoxifen-resistance via enhanced mitochondrial metabolism, glycolysis and Rho-GDI/PTEN signaling: Implicating TIGAR in somatic resistance to endocrine therapy.
    Fiorillo M; Sanchez-Alvarez R; Sotgia F; Lisanti MP
    Aging (Albany NY); 2018 Dec; 10(12):4000-4023. PubMed ID: 30573703
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance.
    Miller TW; Balko JM; Ghazoui Z; Dunbier A; Anderson H; Dowsett M; González-Angulo AM; Mills GB; Miller WR; Wu H; Shyr Y; Arteaga CL
    Clin Cancer Res; 2011 Apr; 17(7):2024-34. PubMed ID: 21346144
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tamoxifen-resistant breast cancer cells possess cancer stem-like cell properties.
    Liu H; Zhang HW; Sun XF; Guo XH; He YN; Cui SD; Fan QX
    Chin Med J (Engl); 2013 Aug; 126(16):3030-4. PubMed ID: 23981606
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Napabucasin Attenuates Resistance of Breast Cancer Cells to Tamoxifen by Reducing Stem Cell-Like Properties.
    Liu X; Huang J; Xie Y; Zhou Y; Wang R; Lou J
    Med Sci Monit; 2019 Nov; 25():8905-8912. PubMed ID: 31760402
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.